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Osteosarcoma (OS) is the most common type of primary solid tumor that develops in bone. Although standard chemotherapy has
significantly improved long-term survival over the past few decades, the outcome for those patients with metastatic or recurrent
OS remains dismally poor and, therefore, novel agents and treatment regimens are urgently required. A hypothesis to explain the
resistance of OS to chemotherapy is the existence of drug resistant CSCs with progenitor properties that are responsible of tumor
relapses and metastasis. These subpopulations of CSCs commonly emerge during tumor evolution from the cell-of-origin, which
are the normal cells that acquire the first cancer-promotingmutations to initiate tumor formation. InOS, several cell types along the
osteogenic lineage have been proposed as cell-of-origin. Both the cell-of-origin and their derived CSC subpopulations are highly
influenced by environmental and epigenetic factors and, therefore, targeting the OS-CSC environment and niche is the rationale
for many recently postulated therapies. Likewise, some strategies for targeting CSC-associated signaling pathways have already
been tested in both preclinical and clinical settings. This review recapitulates current OS cell-of-origin models, the properties of
the OS-CSC and its niche, and potential new therapies able to target OS-CSCs.
1. Introduction
OS is a malignant neoplasm in which the neoplastic cells
produce bone and is the most frequent primary sarcoma
of the skeleton. The tumor is primary when the underlying
bone is normal and secondary when the bone is altered
by conditions, such as prior irradiation, coexisting Paget
disease, infarction, or other disorders. It has a bimodal age
distribution with most cases developing between the ages of
10–16 years and a second smaller peak in older adults (30% of
cases in patients over 40 years) [1]. In addition, OS is themost
common radiation-induced sarcoma. It has an unknown
etiology, although there is an increased incidence of primary
OS associated with several genetic syndromes such as Li-
Fraumeni, hereditary retinoblastoma, and RothmundThom-
son (see below).
Primary OS may arise in any bone, although the vast
majority originate in the long bones of the extremities, espe-
cially the distal femur (30%), followed by the proximal tibia
(15%), and proximal humerus (15%), which represent sites
containing the most proliferative growth plates. Within long
bones, the tumor is usually (90%) located in the metaphysis
and arises as an enlarging and palpablemass, with progressive
pain [2].
The hallmark diagnostic feature of OS is the detection
of osteoid matrix produced by the neoplastic cells. However,
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the most common type of OS, conventional OS, has a very
broad spectrum of histological appearances and is subclassi-
fied according to the predominant type of stroma (osteoblas-
tic, chondroblastic, fibroblastic, giant cell rich, etc.), although
this subclassification has no prognostic relevance [1].
At present, surgery with chemotherapy is the first-line
treatment for most OS [3]. Almost all patients receive
neoadjuvant intravenous combinational chemotherapy (dox-
orubicin and cisplatinwith orwithoutmethotrexate) as initial
treatment. Surgical resection of the primary tumor with ade-
quate margins is an essential component of the curative strat-
egy for patients with localized OS. If complete surgical resec-
tion is not feasible or if surgical margins are inadequate, radi-
ation therapymay improve the local control rate.The postop-
erative chemotherapy regimen usually depends on the extent
of tumor necrosis observed [1, 3].
Advances in the clinical management of OS have led
to a significant increase in 5-year survival rates, which in
most centers now largely exceed 50%. However, survival rates
for patients presenting with metastatic and recurrent disease
have historically remained essentially unchanged with a sur-
vival rate below 20%, highlighting the need for a better under-
standing of the disease leading to the development of novel
therapies [4].
2. Genomics of OS
OS is characterized by the presence of complex karyotypes
indicative of severe chromosomal instability. This accumula-
tion of barely recurrent genetic alterations hinders the identi-
fication of OS-driver genes. A powerful causal-effect relation
between specific gene alterations andOS initiation came from
studies of human hereditary disorders characterized by a
predisposition to the development ofOS [5, 6].The functional
validation of these genomic alterations as driver events was
confirmed inmousemodels [5, 7].The strongest genetic asso-
ciation for sporadic and hereditary OS is with the retinoblas-
toma (RB) and the P53 tumor suppressor genes; meanwhile
other relevant alterations includemutations in other cell cycle
regulators, oncogenes, and DNA helicases [5, 6].
Li-Fraumeni and hereditary retinoblastoma syndromes
are caused by heterozygous germ-line mutations of P53 and
RB, respectively, and patients presenting with these disorders
have a higher predisposition to a range of cancers, including
OS [8, 9]. Importantly, mutations in P53 and/or RB genes
and other components of their pathways are also common in
sporadic OS, suggesting a relevant role for alterations in these
tumor suppression genes or their related signaling pathways
in OS development [5, 6, 10, 11]. On this basis, several P53
and/or RB-deficient mouse models have been developed
to model sarcomagenesis [5, 12]. The most productive OS
models have been developed using conditional mesenchy-
mal/osteogenic lineage-restricted mutation of P53 and RB
(see below). These models indicate that P53 inactivation is
an initiating event in OS [13–15]. On the other hand, the
depletion of RB alone was not sufficient to induce sarcoma
formation in mice. Notably, RB mutation strongly reduced
the latency required for sarcoma formation in P53-deficient
mice, although it decreased the proportion of OS formed
[13, 15]. It was reported that RB is needed to promote
the osteogenic differentiation program of mesenchymal
stem/stromal cells (MSCs) [16] and, therefore, it could be
speculated that RBmutations synergize with P53 inactivation
in OS formation only when mutations occur in osteogenic-
committed cell types; meanwhile it could favor other sarcoma
phenotypes when mutated in more immature cell types (see
below).
Other genes involved in P53 or RB signaling have also
been found to bemutated in sporadic OS [6, 17]. For example,
the INK4A/ARF locus, which encodes for P16INK4A and
P19ARF genes, is deleted in approximately 10% of OS [18, 19].
P16INK4A and P19ARF proteins contribute to the stabiliza-
tion of RB and P53 proteins through the inhibition of cyclin-
dependent kinase 4 (CDK4) and mouse double minute 2
homolog (MDM2) repressors, respectively [20]. Interestingly,
the region 12q13, containing CDK4 and MDM2, is amplified
in up to 10% of OS [6, 21]. In addition, the absence of
expression of P16INK4A correlated with a decreased survival
in pediatric OS, while the amplification of MDM2 has been
associated with the development of metastases in OS [6, 22].
The amplification and/or increased expression of other cell
cycle genes, such as CyclinsD1 and E, have also been reported
in OS, further highlighting an important role of defective cell
cycle regulation in OS development [17, 23].
Several oncogenes like C-FOS, C-JUN, and C-MYC also
play a role in OS development. C-FOS, C-JUN N-terminal
kinase, and C-JUN were found elevated in OS and its expres-
sion and activation were associated with the progression of
human OS [24–26]. Transgenic mice overexpressing C-FOS
developed OS, further suggesting a role in OS pathogenesis
[27]. C-MYC amplification was found in sporadic OS and OS
associated with Paget’s disease [28, 29] and, clinically, high
C-MYC expression correlates with worse outcome in OS
patients [30].
A recent study using a Sleeping Beauty transposon-based
forward genetic screen in mice, with or without somatic
loss of P53 restricted to committed osteoblast progenitors,
identified 36 putative protooncogenes and 196 potential
tumor suppressor genes. Among these OS-driver candidates
the protumorigenic role of PTEN and the axon guidance
genes SEMA4D and SEMA6D were functionally validated.
Moreover, this study highlighted an enrichment of genes
involved in PI3K-AKT-mTOR, MAPK, and ERBB signaling
cascades [51]. Confirming the heterogeneity of OS, an exome
sequencing-based study showed that identified candidateOS-
driver genes were associated with the development of a small
set of tumors, suggesting that multiple oncogenic pathways
drive the characteristic chromosomal instability during OS
development. However, the overall mutation signatures in
these tumors were reminiscent of BRCA1/2 deficient tumors,
a finding with possible therapeutic implications [52]. Com-
parative genomic hybridization analysis combined with gene
expression data also resulted in the identification of genomic
alterations associated with a small proportion of OS, which
may play a role in the OS pathogenesis. For instance, the cell
division-related genes MCM4 and LATS2, the antiapoptotic
genes BIRC2 and BIRC3, and other genes including CCT3,
COPS3, and WWP1 were reported to be found as potential
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Figure 1: Cell-of-origin for OS. The figure shows the most relevant
cell types present in the bone microenvironment. MSCs, repre-
sented in a perivascular niche, and their derived cell types along
the osteogenic lineage, such as the osteoblasts (OSB), are strong
candidates to acquire the first cancer-promoting mutations and
initiate OS formation.
OS drivers [53–55]. Likewise, genomic analysis indicated that
ossification factor genes such as MET, TWIST, and APC are
frequently mutated in pediatric high-grade OS and these
alterations correlated to a worse outcome, thus suggesting a
role in OS development [56].
Other genetic and epigenetic alterations likely involved in
OS pathogenesis includemutations inRECQL4DNAhelicase
associated with the OS-predisposing Rothmund Thomson
syndrome, amplification/mutation in the osteogenic fac-
tor RUNX2, loss of heterozygosity of FGFR2 and BUB3,
enhanced telomerase activity, deletion of PRKAR1A, and
reduced expression of WWOX or hypermethylation of HIC1
in P53 mutated tumors among others [5, 7, 57–61].
3. Cell-of-Origin for OS
The cell-of-origin concept refers to the normal cell type that
acquires the first cancer-promoting mutations and initiates
tumor formation [62]. During the last 10 years mounting
evidence has placed MSCs and/or their immediate lineage
progenitors as the most likely cell-of-origin for many types
of sarcomas including OS [12, 63, 64] (Figure 1). Both
translocation- and non-translocation-associated sarcomas
have been modeled by introducing relevant mutations into
MSC [12, 64–66]. In the case of OS, most of the cell-of-origin
models are based on mutated P53, alone or in combination
with RB inactivation, in the mesenchymal/osteogenic lineage
of mouse models or in murine MSC [63]. By crossing mice
with conditional (floxed) alleles of P53 and/or RB with mice
that have the CRE recombinase gene under the control of
different tissue-restricted promoters, several groupswere able
to generate OS development in vivo. Thus, the inactivation of
P53 and/or RB in early mesenchymal progenitors of embry-
onic limb buds through PRX1-driven CRE expression (PRX1-
CRE) resulted in sarcoma development, presenting an OS
incidence of 60% in P53−/−mice and 20–30% in P53−/−RB−/−
mice, where most of the alternate tumors formed poorly
differentiated soft tissue sarcomas [14, 16]. Meanwhile,
the inactivation of these cell cycle regulators in osteoblast pre-
cursors [OSX1 (Osterix)-CRE] resulted in a higher incidence
of OS formation in both P53−/− (100%) and P53−/−RB−/−
mice (between 53 and 100%) [13, 15, 16]. Similarly, ShRNA-
mediated depletion of P53, together with CRE-mediated
inactivation of RB in osteoblast precursors (OSX1 restricted),
resulted in a delayed and consistent formation of OS, present-
ing a higher degree of osteoblastic differentiation than other
CRE-based models [67]. Within the osteogenic differentia-
tion lineage, targeting of P53 in mature osteoblasts, using
COL1A1- (collagen-1-alpha-1-) driven CRE expression to tar-
get P53 or OCN- (Osteocalcin-) driven expression of SV40-
T antigen to inactivate P53 and RB, also resulted in high OS
formation incidence (85–100%) [14, 68]. Moreover, another
study using a SV40 immortalized murine osteocyte cell line
suggests that fully differentiated osteocytes may also serve
as an OS-initiating cell [69]. Besides P53 deficiency-based
OS models, it has been proven that the expression of the
intracellular domain of NOTCH1 (NICD), leading to con-
stitutive NOTCH activation, in osteoblasts (COL1A1-driven
expression) was sufficient to induce the formation of bone
tumors, including OS [70]. Moreover, NOTCH activation
combined with loss of P53 synergistically accelerates OS for-
mation. Notably, the activation of NOTCH in mesenchymal
progenitors or in osteoblast precursors produces embryonic
lethality [70]. Similarly, mice with upregulated Hedgehog
(HH) signaling inmature osteoblasts with aP53 heterozygous
background developed OS with high penetrance [71].
These results support the concept that OS originates in
the population of cells that undergoes osteoblast commit-
ment rather than in immature MSC. Nevertheless, these
experiments also show that, although presenting at a lower
incidence, early mesenchymal progenitors targeted with
relevant mutations could also initiate OS formation, most
likely influenced by certainmicroenvironment signals. In this
regard, the comparison in a single study of the OS formation
ability of P53/RB-disrupted immature MSC (PRX1-CRE) and
osteoblast committed cells (COL1A1-CRE and OCN-CRE)
confirmed that all types of cells were able to initiateOS forma-
tion and showed that the level of osteoblastic differentiation
of tumors did not correlate with the degree of differentiation
of the cell-of-origin, suggesting that epigenetic dedifferentia-
tionmechanisms could be active inmature osteoblasts during
osteosarcomagenesis [72]. The fact that early progenitors
might represent a cell-of-origin for OS is also strengthened
by the observation of different histological subtypes, which
may reflect the ability of these progenitors to undergo other
differentiation pathways besides osteogenesis.
Studies using murine MSC containing CRE-inactivated
P53 and/or RB alleles also reveal relevant clues about the
nature of the OS-initiating cell and the factors condition-
ing their sarcomagenic potential. P53−/− and P53−/−RB−/−
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adipose-derived-MSC (ASC) or BM-derived-MSC (BM-
MSC) give rise to leiomyosarcoma-like tumors when injected
subcutaneously into immunodeficient mice [72–74]. Oth-
erwise, when BM-MSCs were differentiated along the
osteoblastic lineage before CRE-mediated deletion of P53
and RB, they generated OS-like tumors upon subcutaneous
injection into immunodeficient mice, whereas P53−/−RB−/−
ASC-derived osteogenic progenitors did not display tumori-
genic potential [74]. These data highlight the differences in
the sarcomagenic potential of MSC from different tissues
and indicate that a certain level of osteogenic differentiation
of BM-MSC is needed for the development of the OS phe-
notype. Nevertheless, orthotopic (intrabone or periosteal)
inoculation of P53−/− and P53−/−RB−/− BM-MSC and ASC
undifferentiated MSC consistently generated osteoblastic OS
displaying human OS radiographic and histological features
alongside metastatic potential. Importantly, all the histologi-
cal and radiological OS-related features were less evident or
completely lost in the areas of the tumor distant from the
recipient bone, thus demonstrating that bone microenviron-
mental signals play a role in osteogenic differentiation and
sarcomagenesis by defining the sarcoma phenotype [75]. In
addition, an ectopic model to assay osteosarcomagenesis that
relies on the use ofP53−/−RB−/−MSCembedded in hydroxya-
patite/tricalciumphosphate ceramics also demonstrates a rel-
evant contribution of bone microenvironmental factors, like
bonemorphogenic protein 2 (BMP2) and calcified substrates,
in the acquisition of the OS phenotype [75].
Furthermore, evidence of undifferentiated MSC as cell-
of-origin for OS comes from the introduction of other
oncogenic events into undifferentiated BM-MSC, like the
expression of C-MYC in a P16INK4A−/−P19ARF−/− genetic
background or the aneuploidization accompanied by the loss
of the INKAA locus, resulting in OS development [76, 77].
Additionally, similar gene expression signatures were found
between human OS samples and undifferentiated MSC or
osteogenic-committed MSC [78], suggesting that OS may
develop from both osteogenic progenitors and undifferenti-
ated MSC.
Finally, extraskeletal OS is a very rare type of soft tissue
mesenchymal neoplasm that produces osteoid. It could be
speculated that, rather than BM-MSC, extraskeletal OS could
be initiated by MSCs from soft tissues (muscle-derived MSC,
ASC, etc.) presenting mutations that favor osteogenic differ-
entiation and/or influenced by pathologically osteogenic sig-
nals from themicroenvironment [79]. In this regard this type
of tumors could be related to fibrodysplasia ossificans pro-
gressiva, a rare genetic disorder of connective tissue charac-
terized by the presence of activating mutations in the ACVR1
gene, which encode a BMP type I receptor [80].
Overall, the most likely situation is that either MSC-
derived osteogenic progenitors or undifferentiated MSCmay
represent the cell-of-origin for OS under the influence of
proper microenvironmental or epigenetic signals.
4. Osteosarcoma Cancer Stem Cell
Experimental evidence supports the notion that sarcomas are
hierarchically organized and sustained by a subpopulation
of self-renewing cells that can generate the full repertoire of
tumor cells and display tumor reinitiating properties [12, 81–
83]. In the most likely scenario, these CSC subpopulations
emerge after the accumulation of further epigenetic and/or
genetic alterations in a cell within the aberrant population,
initially generated by the cell-of-origin [62], that is, MSC-
derived cell types.
Several methods have been developed to isolate and/or
enrich subpopulations with stem cell properties within
the tumors [82–85]. The isolation of OS-CSC was first
achieved on the basis of their ability to form spherical
and clonal expanding colonies (sarcospheres) in anchorage-
independent and serum-starved conditions [86–88]. This
sarcosphere formation may be further improved by repro-
ducing the hypoxic conditions of tumor microenvironment
[89]. In addition, OS-CSCs are commonly isolated by sorting
cells according to the expression of specific surface markers
associated with stemness and/or tumorigenesis. For example,
CD133+ [90–92], STRO1+ CD117+ [93], and CD271+ popula-
tions [94] sorted from OS cell lines demonstrated CSC-like
features. Other methods used to isolate OS-CSCs include the
identification of a “side population” of cells able to exclude
fluorescent dyes, alone or in combination with surface mark-
ers like CD248 [95, 96]; the sorting of cells with aldehyde
dehydrogenase 1 (ALDH1) activity [97, 98]; the tracking of
subpopulations that express pluripotency-associated genes,
such as OCT-4 [99]; the enrichment of subpopulations
with high telomerase activity [100, 101]; or the long-term
treatment with chemotherapy [102, 103]. Reinforcing their
expected mesenchymal progenitor origin, many of these
sarcoma-initiating cells expressMSCmarkers [86, 93, 99, 104]
and retain in vitro differentiation properties, giving rise to
adipogenic, chondrogenic, and osteogenic lineages [86, 104].
These CSC commonly show increased expression of the
pluripotent stem cell markers OCT3/4, NANOG, and SOX2
[87, 89, 105, 106]. Remarkably, SOX2 has been reported to
identify a population of CSC in OS required for self-renewal
and tumorigenesis [107]. Importantly, CSCs isolated fromOS
are able to self-renew and sustain tumor generation in serial
transplantation experiments and are associated withmetasta-
sis and drug resistance [89, 93, 96, 98, 105, 107].This increased
chemoresistance of CSC subpopulations has been associated
with an increase in the DNA repair ability, with an inhibition
of the apoptotic signaling, with increased levels of lysosomal
activity due to the overexpression of vacuolar ATPse [108],
and, specially, with a gain in the drug efflux capacity due to
the overexpression of the ABC transporters [96, 102, 105, 109–
111]. In this line, the inhibition of the ABC transporters is
able to sensitize OS-derived sarcosphere to doxorubicin [112].
Therefore, it is clear thatOS-CSCs possess specific properties,
which make them more resistant to therapies.
Similar to normal stem cells, microenvironmental niches
may play a role in OS-CSC regulation [113]. In this regard,
many bonemicroenvironment signals, including thosemedi-
ated by fibroblastic growth factor (FGF), transforming
growth factor 𝛽 (TGF-𝛽), insulin-like growth factor 1 (IGF1),
BMP, vascular endothelial growth factors (VEGF), hypoxia
inducible factors (HIF1), wingless-type MMTV integration
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Figure 2: OS-CSC niches. The figure represents possible niches for
CSCs inOS. Suggested locations for CSCs are the perivascular niche,
the endosteal niche, and areas of poor vascularization (hypoxic
niche).
site family (WNT), HH, or NOTCH among others, are dereg-
ulated inOS and seem to be involved in the regulation of their
self-renewal, differentiation, growth, drug resistance, and/or
metastatic potential of OS-CSC subpopulations (reviewed in
[2]).Three types of nicheswithin the bonemicroenvironment
where these signaling pathways are particularly active could
be inferred to be the location OS-CSCs: the perivascular
niche, the hypoxic niche, and the endosteal niche (Figure 2).
OS is a highly vascularized tumor and as OS-CSCs seem to
arise fromMSC it is likely thatOS-CSCsmay be located in the
same perivascular niche already well-described for normal
MSCs. Besides providing stemness signals, this perivascular
location would favor migration and metastasis of CSC [84,
114]. On the other hand, the bone is a hypoxic environment
and hypoxia-induced signaling is a key environmental factor
involved in stemness maintenance, OS progression, and drug
resistance and therefore could constitute a suitable niche
for OS-CSCs [2, 115]. Finally, the endosteal niche is a rich
environment where tumor cells interfere with the bone
remodeling process, establishing a “vicious cycle” that favors
osteoclast-mediated osteolysis and the subsequent release of
calcium and growth factors (FGF, TGF-𝛽, IGF1, BMP, etc.),
which support stem and tumorigenic properties [2, 116, 117].
5. Cancer Stem Cell Targeted Therapies in OS
Studies concerning the molecular biology of cancer are now
promoting the identification of new potential therapeutic
targets with molecular rationale able to target OS. As a result,
therapies targeting altered signaling are being thoroughly
tested in several clinical trials [58, 118–120] (Table 1). These
strategies included the targeting of the signaling mediated by
receptor tyrosine kinases (EGFR, VEGFR, IGF1R, HER2, or
PDGFR), mTOR, or WNT/𝛽-catenin. In addition, since OS-
CSCs reside within the bone microenvironment and this a
key factor in the regulation of tumor homeostasis, therapies
directed against microenvironmental niche factors could
contribute to the improvement of clinical response [2].There-
fore, several therapeutic strategies have been developed to
target the role of the tumor-promoting osteoclast activity [31–
33, 121], to reduce the vascularization of tumors [34, 122] and
to enhance the immune response against tumors [123–126]
(Table 1).
As seen before, OS-CSCs are resistant to most con-
ventional treatments like radiation and chemotherapy and
are, therefore, responsible for tumor relapses and metastasis.
Hence, in addition to the proposed therapies directed against
specific signaling and/or tumor niches, there is a need for
developing and testing therapies able to target CSC subpopu-
lations inOS. Below,we reviewed currentwork reporting spe-
cific antitumoral activity onOS-CSC subpopulations or CSC-
related features (Table 2).
Broad genomic, metabolomic, and proteomic analyses
have been useful to better characterize OS-CSC and therefore
define potential OS-CSC-specific therapeutic targets with
molecular rationale [58, 127, 128]. Among the reported altered
signaling pathways with therapeutic implications, nuclear
factor 𝜅B (NF-𝜅B) is activated in radioresistant subpopula-
tions of OS cell lines, and these subpopulations could be
sensitized to radiation by parthenolide, an inactivator of
NF-𝜅B [129]. Another NF-𝜅B inhibitor, BRM270, specifically
targeted a multidrug resistant OS stem-like cell population
by increasing their apoptosis rate and thereby reducing
tumorigenic potential [130]. Phosphatidylinositol-3-kinase
(PI3K) is also an interesting therapeutic target due to its high
mutation frequency and its role in regulation of proliferation,
cell cycling, survival, and apoptosis. BYL719, a specific PI3K𝛼
inhibitor, induces cell cycle arrest and inhibition of cell
migration in OS cells, and, therefore, has been postulated to
be useful for multidrug therapeutic approaches [35]. More-
over, another PI3K inhibitor, LY294002, induces cell cycle
arrest and apoptosis in OS-CSC [131].
Developmental signaling pathways like WNT and
NOTCH, which are highly involved in the regulation of
stemness and differentiation, have also been reported to
play a role in OS development [2, 37, 70]. In OS cell lines,
the inactivation of NOTCH and WNT pathways resulted in
sensitization to chemotherapeutic drugs [36]. In addition,
aberrant activeWNT/𝛽-catenin signaling has been described
in the OS-CSC population and has been associated with
SOX2 overexpression and tumorigenicity [38, 132]. On the
other hand, theWNT-antagonist Dickkopf proteins 1 (DKK1)
has been proposed to enhance protumorigenic properties in
OS, in part, through the upregulation of the stress response
enzyme and CSC marker ALDH1A1 [133]. In this case, the
inhibition of the canonical WNT pathway by DKK1 leads
to the activation of noncanonical JUN-mediated WNT
pathways, which mediate the induced tumorigenic effects.
Likewise, NOTCH signaling has been associated with ALDH
activity and increased metastatic potential in OS cells [39].
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Table 1: Selected clinical trials targeting altered signaling and tumor environment in OS∗.
Target Drug Type of drug Clinical trial reference number (NCT number)
Cell membrane receptors
ERBB2 Trastuzumab Monoclonal antibody NCT00023998
IGF1R Cixutumumab Monoclonal antibody NCT01016015/NCT00831844/NCT01614795/NCT00720174
RG1507 Monoclonal antibody NCT00642941
EGFR ZD1839 Inhibitor NCT00132158
PDGFR Erlotinib Inhibitor NCT00077454
Imatinib Inhibitor NCT00031915/NCT00030667
PRGFR/VEGFR Sorafenib Inhibitor NCT01804374/NCT00889057/NCT00880542/NCT00330421/NCT01518413
VEGFR
Pazopanib Inhibitor NCT01759303/NCT02357810/NCT01130623/NCT02180867/NCT01532687/NCT01956669
Bevacizumab Monoclonal antibody NCT00667342
Endostar
(rh-endostatin) Inhibitor NCT01002092
Intracellular signaling
mTOR Everolimus Inhibitor NCT01216826
Ridaforolimus Inhibitor NCT00093080/NCT00538239
WNT/𝛽-catenin Curcumin Inhibitor NCT00689195
Niche cells and their signaling
Osteoclasts Zoledronic acid Bisphosphonate NCT00691236
Pamidronate Bisphosphonate NCT00586846
RANKL Denosumab Monoclonal antibody NCT02470091
Immune system
T cells expressing
GD2 Cells NCT02107963
GD2Bi-armed T
cells Cells NCT02173093
Anti-GD2 Monoclonal antibody NCT00743496/NCT02502786
Stem and natural
killer cells Cells NCT02409576/NCT01807468
Mifamurtide Monocyte/macrophageactivator glycopeptide NCT02441309/NCT00631631
∗Source: https://clinicaltrials.gov/. Osteosarcoma clinical trials: total: 363, open: 122.
ERBB2: Erb-B2 receptor tyrosine kinase 2; IGF1R: insulin-like growth factor 1 receptor; EGFR: epidermal growth factor receptor; PDGFR: platelet-derived
growth factor receptor; VEGFR: vascular endothelial growth factor receptor; mTOR:mechanistic target of rapamycin;WNT: wingless-typeMMTV integration
site family; RANKL: receptor activator of nuclear factor kappa-B ligand.
Therefore, a number of different therapies have been assayed
to target WNT or NOTCH pathways via downregulation,
inactivation, or silencing techniques [2, 37, 40] (Table 1).
Interestingly, curcumin, a natural product that shows high
antitumoral activity against OS cells, is a WNT/𝛽-catenin
antagonist whose antitumor activity seems to be mediated
through the inactivation of NOTCH1 signaling, thereby
linking both signaling pathways [41]. In addition, TGF-𝛽
is also a well-known regulator of bone biology that plays
a relevant role in OS development [42]. The blocking of
TGF-𝛽 signaling using the natural TGF-𝛽/SMAD signaling
inhibitor SMAD7, the inhibitor of TGF-𝛽 receptor complexes
SD-208, or the natural alkaloid halofuginone hindered OS
progression. These treatments reduced in vivo tumorigenic
potential of OS cell lines, repressed tumor-associated bone
remodeling, and inhibited the development of metastasis
[43, 44]. Moreover, TGF-𝛽 signaling activation has been
involved in the induction of stemness, tumorigenicity,
metastatic potential, and chemoresistance in nonstem OS
cells, and, conversely, the blocking of this signaling resulted
in the inhibition of this dedifferentiation process of nonstem
cell populations, thereby highlighting TGF-𝛽 as a potential
therapeutic target [45].
Not surprisingly, microRNAs (miRNAs) are extensively
related to OS development [46]. In a CSC context, a list
of 189 miRNAs that are differentially expressed in OS-CSC
has been reported [127]. Some of these miRNAs, such as
miR-382 and miR-29b-1, were significantly decreased in
human OS and their overexpression resulted in a decrease
in CSC properties, metastatic potential, or chemoresistance,
thus suggesting that these miRNAs could constitute novel
therapeutic strategies to target OS-CSC [47, 48]. On the
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Table 2: Therapeutic agents with reported activity on OS-CSCs subpopulations or related properties.
Therapeutic agent Proposed mechanisms of action Effect on CSC/CSC properties Reference
Parthenolide NF-𝜅B inhibition/oxidative stressinduction
Sensitizes to ionizing radiation reducing the viability of
CD133+ CSCs [31]
BRM270 NF-𝜅B/CDK6/IL6downregulation Induces programmed cell death [32]
BYL719 PI3K inhibition Induces cell cycle arrest and inhibits migration [33]
LY294002 PI3K inhibition Induces cell cycle arrest and apoptosis inOS-sarcospheres [34]
SB431542 TGF-𝛽 inhibition Reduces self-renewal and differentiation and increaseschemosensitivity of OS-sarcospheres [35]
miR-382 expression YB-1 inhibition Decreases OS-CSCs, reduces metastatic potential, andinhibits tumor formation from CD133+ OS cells [36]
miR-29b-1 expression — Reduces sarcosphere formation and induceschemosensitization of OS cells [37]
miR-133a inhibition — Reduces cell invasion of CD133
+ OS cells and suppresses
metastasis in combination with chemotherapy [38]
lncRNA HIF2PUT HIF-2𝛼 Reduces CD133
+ cells and impairs sphere-forming in
OS cells [39]
Metformin AMPK/mTOR signalingalteration
Reduces sphere-forming ability and sensitizes OS cells
to chemotherapeutic agents [40, 41]
Bufalin miR-148a/DNMT1/CDKN1B Inhibits differentiation and proliferation ofOS-sarcospheres [42, 43]
Salinomycin WNT signaling downregulation
Reduces sphere-formation and tumor-initiation ability
of OS cells and sensitizes them to chemotherapeutic
drugs
[44]
Salinomycin-loaded
nanoparticles —
When combined with CD133 aptamers selectively
targets OS-CD133+ cells [45]
Diallyl trisulfide
Upregulation of
tumor-suppressive
miRNAs/inhibition of NOTCH1
signaling/downregulation of
ABCB1
Prevents invasion, angiogenesis, and drug resistance in
OS cells and in combination with methotrexate reduces
OS-CD133+ cells
[46, 47]
MC1742/MC2625 Histone deacetylase inhibition Induces apoptosis and promotes differentiation ofsarcoma CSCs [48]
Vorinostat Histone deacetylase inhibition Reduces metastatic potential of OS cells [49]
Anti-CD47 antibody Increased macrophagephagocytosis Inhibits invasion and metastasis of OS cells [50]
CDK6: cyclin-dependent kinase 6; IL6: interleukin 6; TGF-𝛽: transforming growth factor 𝛽; YB-1: Y box-binding protein 1; HIF-2𝛼: hypoxia inducible factors
2𝛼; AMPK: AMP-activated protein kinase; mTOR: mechanistic target of rapamycin; DNMT1: DNA (cytosine-5-)-methyltransferase 1; CDKN1B: cyclin-
dependent kinase inhibitor 1B; WNT: wingless-type MMTV integration site family; ABCB1: ATP-binding cassette subfamily B member 1.
other hand, high levels of miR-133a and CD133 correlated
with poor prognosis in OS and the inhibition of miR-133a
associated with chemotherapy suppressed lung metastasis
and prolonged survival in preclinical models of OS [49].
Moreover, other miRNAs likemiR-215 andmiR-140 have also
been related to OS chemoresistance [50, 134]. In addition, a
recent report shows that the overexpression of the novel long
noncodingRNAHIF2PUT, involved in the regulation ofHIF-
2𝛼 expression, markedly inhibited proliferation, migration,
and stem cell features in OS cells, thus providing a proof of
principle for testingHIF2PUT in future therapeutic strategies
[135].
Several natural compounds with reported antitumoral
activity in OS have recently been shown to demonstrate
specific inhibitory effects in OS-CSC (Table 2). Thus, besides
inhibiting proliferation, invasion, and metastatic potential in
OS cells, the hypoglycemic agent metformin also induces
a marked reduction of the self-renewal and differentiation
potential of CSC subpopulations and sensitizes OS cell to
cisplatin [136, 137]. In a similar way, bufalin inhibits the
differentiation and proliferation of OS-CSC through a mech-
anism regulated by miR-148a [138, 139]. Also, the polyether
ionophore antibiotic salinomycin has demonstrated spe-
cific antitumoral activity against OS-CSC [140]. Moreover,
salinomycin-loaded nanoparticles conjugated with CD133
aptamers highly increase the therapeutic effect of the drug
on CD133+ OS-CSC [141]. Another natural derivative with
reported antitumoral activity in OS is diallyl trisulfide, which
can reverse drug resistance through the downregulation of
ABCB1, and, in combination with methotrexate, is able to
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reduce the CD133+ subpopulation of drug resistant human
OS cells [142]. Antitumoral effects of diallyl trisulfide seem
to be mediated by the upregulation of tumor-suppressive
miRNAs associated with an inhibition of NOTCH1 signaling
[143]. Additionally, several histone deacetylase inhibitors
have demonstrated antitumoral activity in OS, including the
induction of differentiation in OS-CSC and the reduction of
the metastatic potential [144, 145].
Finally, immunotherapy is an attractive option to target
CSC subpopulations. Thus, the treatment of human OS cell
lines with T cells expressing a specific chimeric antigen to
target the human epidermal growth factor receptor ERBB2
was able to efficiently decrease the sarcosphere formation
capacity and the ability to generate OS in vivo, suggesting
that this immune-based strategy is able to target CSC sub-
populations [125]. In addition, the membrane receptor CD47,
which plays an important role in the mechanisms of tumor
immune escape, has been found overexpressed inOS samples
and highly expressed in cell subpopulations expressing the
CSCmarker CD44. Notably, the blockade of CD47 by specific
antibodies suppressed the invasive ability and the metastatic
potential of OS cells, suggesting a potential use for these anti-
CD47 antibodies in the treatment of OS [146].
It is important to mention that CSC subpopulations are
heterogeneous and different subpopulations may exist within
a tumor with different genetic alterations. Moreover, these
subpopulations are highly dynamic and there are processes of
dedifferentiation and phenotype switching whichmay render
CSC resistant to a specific CSC therapy [147]. In this regard,
future therapies should combine different treatments to target
both non-CSCs andCSCs, and those CSC-specific treatments
should target multiple pathways altered in different subsets
of CSCs within the tumor. These broader spectrum thera-
peutic approaches include immune-based treatments and/or
therapy targeting tumor microenvironment. In addition,
inhibition of transcription factors presenting altered activity
offers a promising choice since they are pivotal points in
signaling pathways and therefore their inhibition may block
several routes involved in tumor progression. In this regard,
inhibition of SP1 was able to eliminate CSCs in soft tissue
sarcoma models [148].
6. Conclusions
In themost likely scenario,OSdevelopment is initiated by dif-
ferent cell types along the mesenchymal-osteogenic lineage
targeted with relevant oncogenic lesions, like the inactivation
of the tumor suppressor genes P53 and RB, and highly influ-
enced by bonemicroenvironment signals. During tumor evo-
lution, CSC subpopulations emerge after the accumulation
of further epigenetic and/or genetic alterations in a subset
of tumor cells. During the past decades, chemotherapy for
treatment of OS has improved the overall survival for patients
significantly. However, despite impressive advances, there are
very little novel therapeutic agents that target tumors which
aremetastatic or refractory to current chemotherapy, creating
a real need for the development of more biologically focused
treatment regimens. OS represent a heterogeneous type of
tumors, for which broader spectrum therapeutic approaches
should be proposed. These strategies may include com-
bined targeted therapies, immune-based treatments, and/or
therapy targeting tumor microenvironment. Recent studies
have highlighted the importance of OS-CSCs, which have
been associatedwith chemoresistance, relapse, andmetastasis
events. More research aimed towards the characterization
of CSC biology and evolution during tumor progression is
needed to develop powerful methods of detection and effi-
cient therapies. Targeting the tumor OS-CSCs or disrupting
the interaction between OS-CSCs and their bone niche also
constitutes a valuable approach, with promising clinical trials
ongoing that could yield exciting new therapies for the future.
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